Clinical trial
A Phase 2 Study of Cannabidiol as a New Treatment for Autism Spectrum Disorder in Children and Adolescents
NCT03900923 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Cannabidiol as a New Treatment for Autism Spectrum Disorder in Children and Adolescents
- Lead sponsor
- NYU Langone Health
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 12, 2019
- Completion date
- May 4, 2023
- Enrollment
- 29 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.